⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024

Supplementary Information 1 from Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition

Leonard Schmiester Fara Brasó‐Maristany Blanca González‐Farré Tomás Pascual Joaquín Gavilá Xavier Tekpli Jürgen Geisler Vessela N. Kristensen Arnoldo Frigessi Aleix Prat Alvaro Köhn‐Luque

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplementary information containing detailed description of the modeling approach.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schmiester et al. (2024) studied this question.

synapsesocial.com/papers/68e598d9b6db643587533186 https://doi.org/10.1158/1078-0432.26926531

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Information 1 from Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition2024
2Data from Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition2024
3Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition2024 · 5 citations
4Abstract PO4-14-09: A computational model of the mechanisms of action of combined endocrine therapy and CDK4/6 inhibition predicts outcome in patients with Luminal B breast cancer2024
5Abstract PS1-11-08: Integrative modeling of multimodal real-world data for improved risk stratification of first-line CDK4/6 inhibitor outcomes in patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancercohort · 2026
6Supplementary Data from A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer2024
7Supplementary Data from A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer2024
8Abstract LB015: Precision biomarkers for cdk4/6 inhibitors plus endocrine treatment inHR+/HER2-breast cancer: External validation of mechanistic and hybrid predictive models across multiple neoadjuvant trialsHuman Clinical Trial · 2026